Head and Neck Cancer

Attenuated Virus Studied as Cancer Treatment in Phase I Trial

Published in Cancer Weekly, May 16th, 2000

Preliminary results of a Phase I trial conducted by researchers at CRC Beatson Labs in Scotland indicate that a E1B 55 kDa gene-deleted adenovirus, which kills p53-deficient cells, may show promise as an oncologic agent. This attenuated virus has been given the name Onyx-015.

The initial results of this study were reported by I. Ganly et al. in Clinical Cancer Research ("A Phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer," Clin Cancer Res, 2000;6(3):798-806).

Twenty-two patients were given an intratumor injection of Onyx-015. Twenty-one of the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2000-05-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry